Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor

Endocrinology

Volumn 146, Issue 11, 2005, Pages 4609-4618

  Knowlden, J M ^a   Hutcheson, I R ^a   Barrow, D ^a   Gee, J M W ^a   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE; RECEPTOR BLOCKING AGENT; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WILD TYPE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 26844487041     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-0247     Document Type: Article

References (48)

1. Surmacz E 2000 Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5:95-105
2. Cullen J, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N 1990 Insulin-like growth factor expression and function in human breast cancer. Cancer Res 50:48-53
3. Sachdev D, Yee D 2001 The IGF system and breast cancer. Endocr Rel Cancer 8:197-209
4. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y 1986 Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512
5. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R 1999 Multiple signaling pathways of the insulin-like growth factor I receptor in protection from apoptosis. Mol Cell Biol 19:7203-7215
6. Brodt P, Samani A, Navab R 2000 Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101-1107
7. Rocha RL, Hilsenbeck SG, Jackson JG, Van Den Berg CL, Weng C, Lee AV, Yee D 1997 Insulin-like growth factor binding protein 3 and insulin receptor substrate 1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103-109
8. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM 1997 IGF-I receptor and cyclin D1 expression influence cellular radiosensitivity and local recurrence after lumpectomy and radiation. Cancer Res 57:3079-3083
9. Hamelers IHL, Steenbergh PH 2003 Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Rel Cancer 10:331-345
10. Yee D, Lee AV 2000 Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5:107-115
11. Lee AV, Yee D 1995 Insulin-like growth factors and breast cancer. Biomed Pharmachother 49:415-421
12. Guvakova MA, Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606-2610
13. Parisot JP, Hu XF, DeLuise M, Zalcberg 1999 Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79:693-700
14. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR 1993 Type I IGF receptor and acquired tamoxifen resistance in oestrogenresponsive human breast cancer cells. Eur J Cancer 29A:2256-2264
15. Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI 2004 Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814
16. Olayioye, MA, Neve RM, Lane HA, Hynes N 2000 The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167
17. Nicholson RI, Gee JMW, Jones H, Harper ME, Wakeling AE, Willsher P, Robertson JFR 1997 erbB signalling and endocrine sensitivity of human breast cancer. In: RB Lichtner, RN Harkins, eds. Ernst Schering Research Foundation Workshop 19: EGF receptor in tumor growth and progression. Boston: Springer-Verlag Schering Publications; 105-128
18. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW 1993 Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A:1018-1023
19. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JF, Ellis IO, BlameyRW1994 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125
20. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH 1992 Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121
21. Long B, McKibben BM, Lynch M, van den Berg HW 1992 Changes in epidermal growth factor expression and response to ligand-associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65:865-869
22. El-Zarruk AA, van den BergHW1999 The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett 142:185-193
23. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95
24. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG 1995 MCF-7 breast cancer cells over expressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117
25. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044
26. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788
27. Shou J, Suleiman M, Lee AV, Wakeling A, Osborne K, Schiff R 2003 Blocking EGFR family receptors with gefitinib ("Iressa," ZD1839) blocks selected actions of IGF-1 signaling through IGF-1R. Proc AACR 44:4865 (Abstract)
28. Ahmad T, Farnie G, Bundred NJ, Anderson NG 2003 The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 279:1713-1719
29. Balana ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV 2001 Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20:34-47
30. Burgaud JL, Baserga R 1996 Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res 223:412-419
31. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM 2000 Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275:22583-22589
32. Hurbin A, Dubrez L, Coll JL, Favrot MC 2002 Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 277:49127-49133
33. Wang D, Patil S, Li W, Humphrey LE, Brattain MG, Howell GM 2002 Activation of the TGFα autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21:2785-2796
34. Coppola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R, Baserga R 1994 A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 14:4588-4595
35. Vardy DA, Kari C, Lazarus GS, Jensen PJ, Zilberstein A, Plowman GD, Rodeck U 1995 Induction of autocrine epidermal growth factor receptor ligands in human keratinocytes by insulin/insulin-like growth factor-1. J Cell Biol 163:257-265
36. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, StreuliCH2002 Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulinlike growth factor receptor. J Biol Chem 277:27643-27650
37. Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D 1997 Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138:1427-1433
38. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA 2000 SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 23:9018-9027
39. Knowlden JM, Gee JM, Bryant S, McClelland RA, Manning DL, Mansel R, Ellis IO, Blamey RW, Robertson JF, Nicholson RI 1997 Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin Cancer Res 3:2165-2172
40. Swolin D, Brantsing C, Matejka G, Ohlsson C 1996 Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. J Endocrinol 149:397-403
41. Brockdorff BL, Heiberg I, Lykkesfeldt AE 2003 Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor I. Endocr Relat Cancer 10:579-590
42. McCotter D, van den Berg HW, Boylan M, McKibben B 1996 Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett 99:239-245
43. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F 1996 Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271:11477-11483
44. Gee JM, Rubini M, Robertson JF, Ellis IO, Gutteridge E, Nicholson RI 2003 Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer. Breast Cancer Res Treat 82(Suppl 1):429 (Abstract)
45. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR 2004 SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64:6166-6173
46. Shah BH, Farshori MP, Jambusaria A, Catt KJ 2003 Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 278:19118-19126
47. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ 1999 c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274:8335-8343
48. Stover DR, Becker M, Liebetanz J, Lydon NB 1995 Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 α. J Biol Chem 270:15591-15597